Search results for " Angiogenesi"

showing 10 items of 70 documents

Expression Pattern of Angiogenic Factors in Healthy Heart in Response to Physical Exercise Intensity

2019

Recently, many studies showing the regeneration potential of both cardiac and hematopoietic stem cells in adult heart following injury were definitively retracted by the literature. Therefore, stimulating myocardial angiogenesis becomes to be important for preventing cardiovascular diseases. Regular endurance exercise has been reported to induce capillary growth in healthy and diseased myocardium resulting in cardioprotective phenotype. Previously, we demonstrated a significantly increased capillary proliferation in mouse hearts following 30 and 45 days of endurance training. In the present study, we examined the localization and expression pattern of vascular endothelial growth factor rece…

0301 basic medicinemedicine.medical_specialtyAngiogenesisPhysiologyPhysical exercisecapillary growthheart030204 cardiovascular system & hematologylcsh:Physiology03 medical and health sciencesParacrine signallingchemistry.chemical_compoundangiogenesis0302 clinical medicineexercise intensityendurance trainingEndurance trainingphysical exercisePhysiology (medical)Internal medicineMedicineskeletal muscleOriginal ResearchSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' Sportivebiologylcsh:QP1-981business.industryhypoxiaHypoxia (medical)Vascular endothelial growth factorNitric oxide synthase030104 developmental biologyEndocrinologychemistryExercise intensitybiology.proteincardiovascular systemmedicine.symptomheart skeletal muscle endurance training angiogenesis physical exercise capillary growth hypoxia exercise intensitybusinessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie
researchProduct

Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review

2018

The reporting of osteonecrosis of the jaw (ONJ) related to anticancer agents without known antiresorptive properties (non-antiresorptives), such as antiangiogenics, tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, immune checkpoint inhibitors, and cytotoxic chemotherapy is increasing. To review characteristics of ONJ in cancer patients receiving non-antiresorptives. A systematic review of the literature between 2009 and 2017 was conducted by the Bone Study Group of MASCC/ISOO. Of 6249 articles reviewed and from personal communication, 42 ONJ cases related to non-antiresorptives were identified. No gender predilection was noted. Median age was 60 years and ONJ stage 2 wa…

AdultMaleOncologyBRAF inhibitormedicine.medical_specialtymTOR inhibitorsImmune checkpoint inhibitorsInhibitors of angiogenesiTyrosine kinase inhibitorBone resorptionImmune checkpoint inhibitorDelayed diagnosisCytotoxic chemotherapyBone resorption03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineHumans030212 general & internal medicineStage (cooking)AgedBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryOsteonecrosisCancerMiddle AgedCytotoxic chemotherapymedicine.diseasemedicine.anatomical_structureJawOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.

2009

Aims: Essential thrombocythaemia (ET) and primary myelofibrosis (PMF) share some clinical and pathological features, but show different biological behaviour and prognosis. The latest contributions to understanding the nature of these disorders have focused on bone marrow microenvironment remodelling and proliferative stress, recognising megakaryocytes (MKCs) as “key-cells”. The aim of this study was to investigate the apoptotic profile of ET and PMF MKCs in order to further characterise the biology of these disorders. Methods: Bone marrow biopsy samples from 30 patients with ET, and 30 patients with PMF, were immunophenotypically studied for the expression of pro-apoptotic (Fas, Fas-L, Bax,…

AdultMalePathologymedicine.medical_specialtyBiopsyIDIOPATHIC MYELOFIBROSISApoptosisPOLYCYTHEMIA-VERASettore MED/08 - Anatomia PatologicaBiologyPathology and Forensic MedicineImmunophenotypingImmunophenotypingMegakaryocyteBone MarrowmedicineIn Situ Nick-End LabelingHumansTelomerase reverse transcriptaseMyelofibrosisMOLECULAR PERSPECTIVEAgedAged 80 and overTUNEL assayEssential thrombocythemiaC-MPLMUTATION STATUSGeneral MedicineMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureCHRONIC MYELOPROLIFERATIVE DISORDERSCELL-DEATHApoptosisPrimary MyelofibrosisRISK-FACTORSCancer researchBONE-MARROW ANGIOGENESISMYELOID METAPLASIAFemaleBone marrowMegakaryocytesThrombocythemia EssentialJournal of clinical pathology
researchProduct

Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise

2010

J Appl Physiol. 2010 Jul;109(1):60-7. Epub 2010 May 6. Hemopoietic and angiogenetic progenitors in healthy athletes: different responses to endurance and maximal exercise. Bonsignore MR, Morici G, Riccioni R, Huertas A, Petrucci E, Veca M, Mariani G, Bonanno A, Chimenti L, Gioia M, Palange P, Testa U. SourceBiomedical Department, Internal and Specialistic Medicine (DIBIMIS), Section of Pneumology, University of Palermo, Via Trabucco, 180, 90146 Palermo, Italy. marisa@ibim.cnr.it Abstract The effects of endurance or maximal exercise on mobilization of bone marrow-derived hemopoietic and angiogenetic progenitors in healthy subjects are poorly defined. In 10 healthy amateur runners, we collect…

AdultMalemedicine.medical_specialtyPhysiologyNeovascularization PhysiologicAntigens CD34Physical exerciseHematopoietic Cell Growth FactorsSettore BIO/09 - FisiologiaRunningangiopoietin; marathon; circulating progenitors; growth factorsAntigens CDEndurance trainingPhysiology (medical)Internal medicinegrowth factorsmedicineHumansAC133 AntigenProgenitor cellGlycoproteinsErythroid Precursor CellsbiologyAthletesbusiness.industryangiopoietinHealthy subjectsEndothelial Cellscirculating progenitorMiddle AgedCadherinsHematopoietic Stem Cellsbiology.organism_classificationHaematopoiesisEndocrinologyAthletesPhysical EnduranceCytokinesAngiogenesis Inducing Agentsadult; angiogenesis inducing agents; angiopoietin; antigens; athletes; blood; cadherins; cd; cd34; circulating progenitors; cytokines; endothelial cells; erythroid precursor cells; glycoproteins; granulocytes; growth factors; hematopoietic cell growth factors; hematopoietic stem cells; humans; male; marathon; middle aged; neovascularization; peptides; physical endurance; physiologic; physiology; runningAC133 antigenMaximal exercisemarathonPeptidesbusinessGranulocytesJournal of Applied Physiology
researchProduct

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working grou…

2016

The US National Cancer Institute estimates that cardiotoxicity (CTX) from target therapy refers mostly to four groups of drugs: epidermal growth factor receptor 2 inhibitors, angiogenic inhibitors, directed Abelson murine leukemia viral oncogene homolog inhibitors, and proteasome inhibitors. The main cardiotoxic side-effects related to antiepidermal growth factor receptor 2 therapy are left ventricular systolic dysfunction and heart failure. Angiogenesis inhibitors are associated with hypertension, left ventricular dysfunction/heart failure, myocardial ischemia, QT prolongation, and thrombosis. Moreover, other agents may be related to CTX induced by treatment. In this study, we review the g…

AngiogenesisLeftAngiogenesis Inhibitors030204 cardiovascular system & hematologyVentricular Dysfunction Left0302 clinical medicinetyrosine kinase inhibitorNeoplasmstyrosine kinase inhibitorsVentricular DysfunctionMolecular Targeted TherapyEpidermal growth factor receptorSocieties Medicalangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitorABLbiologyDisease ManagementGeneral MedicineItalyCardiovascular DiseasesSupplement Submission030220 oncology & carcinogenesisangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiology; Cardiomyopathies; Cardiotoxicity; Heart Failure; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Ventricular Dysfunction Left; Disease ManagementPractice Guidelines as TopicCardiologyCardiology and Cardiovascular MedicineCardiomyopathiesmedicine.medical_specialtyCardiologyAntineoplastic AgentsRisk AssessmentQT interval03 medical and health sciencesGrowth factor receptorInternal medicineMedicalmedicineHumansMonitoring PhysiologicHeart FailureCardiotoxicitybusiness.industryCancerHER2/epidermal growth factor receptor 2medicine.diseaseangiogenesis inhibitors; HER2/epidermal growth factor receptor 2; tyrosine kinase inhibitors; Cardiology and Cardiovascular MedicineCardiotoxicityangiogenesis inhibitorHeart failurebiology.proteinbusinessSocietiesJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

C1q induces in vivo angiogenesis and promotes wound healing

2011

C1q; angiogenesisangiogenesisChemistryAngiogenesisIn vivoImmunologyCancer researchSettore MED/08 - Anatomia PatologicaWound healingMolecular BiologyC1q
researchProduct

CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA

2015

Background CD90+ liver cancer cells have been described as cancer stem-cell-like (CSC), displaying aggressive and metastatic phenotype. Using two different in vitro models, already described as CD90+ liver cancer stem cells, our aim was to study their interaction with endothelial cells mediated by the release of exosomes. Methods Exosomes were isolated and characterized from both liver CD90+ cells and hepatoma cell lines. Endothelial cells were treated with exosomes, as well as transfected with a plasmid containing the full length sequence of the long non-coding RNA (lncRNA) H19. Molecular and functional analyses were done to characterize the endothelial phenotype after treatments. Results …

Cancer ResearchAngiogenesisAngiogenesis; CD90+ liver cancer cells; Exosomes; Long-non-coding RNA H19; Antigens Thy-1; Cell Adhesion; Cell Line Tumor; Endothelial Cells; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; RNA Long Noncoding; Phenotype; Molecular Medicine; Oncology; Cancer ResearchBiologyCD90+ liver cancer cellsExosomesCell LineSettore BIO/13 - Biologia ApplicataCancer stem cellCell Line TumormedicineCell AdhesionHuman Umbilical Vein Endothelial CellsHumansCD90AntigensThy-1TumorExosomes Long-non-coding RNA H19 CD90+ liver cancer cells AngiogenesisResearchLiver NeoplasmsCancerEndothelial Cellsmedicine.diseaseMicrovesiclesCell biologyEndothelial stem cellPhenotypeOncologyembryonic structuresThy-1 AntigensRNAMolecular MedicineRNA Long NoncodingLong NoncodingAngiogenesisStem cellLiver cancerLong-non-coding RNA H19Molecular Cancer
researchProduct

The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in colla…

2006

Abstract Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibroblast activation protein α are homologous type II transmembrane, homodimeric glycoproteins that exhibit unique prolyl peptidase activities. Human DPP4 is ubiquitously expressed in epithelial and endothelial cells and serves multiple functions in cleaving the penultimate positioned prolyl bonds at the NH2 terminus of a variety of physiologically important peptides in the circulation. Recent studies showed a linkage between DPP4 and down-regulation of certain chemokines and mitogenic growth factors, and degradation of denatured collagens (gelatin), suggesting a role of DPP4 in the cell invasive phenotype. Here, we found the existen…

Cancer ResearchProteasesDipeptidyl Peptidase 4medicine.medical_treatmentBiologyArticleDipeptidyl peptidaseExtracellular matrixFibroblast activation protein alphaCell MovementmedicineHumansSerine proteaseProteaseSerine EndopeptidasesAntibodies MonoclonalEndothelial CellsCell migrationdipeptidyl peptidase IV CD26 seprase fibroblast activation protein α endothelial cell migration angiogenesisExtracellular MatrixUp-RegulationEndothelial stem cellOncologyBiochemistrybiology.proteinGelatinCell Surface ExtensionsCollagenPeptide Hydrolases
researchProduct

MicroRNAs: Promising New Antiangiogenic Targets in Cancer

2014

[EN] MicroRNAs are one class of small, endogenous, non-coding RNAs that are approximately 22 nucleotides in length; they are very numerous, have been phylogenetically conserved, and involved in biological processes such as development, differentiation, cell proliferation, and apoptosis. MicroRNAs contribute to modulating the expression levels of specific proteins based on sequence complementarity with their target mRNA molecules and so they play a key role in both health and disease. Angiogenesis is the process of new blood vessel formation from preexisting ones, which is particularly relevant to cancer and its progression. Over the last few years, microRNAs have emerged as critical regulat…

Cell typeDOWN-REGULATIONArticle SubjectAngiogenesisHUMAN BREAST-CANCERMIR-200 FAMILYlcsh:MedicineAngiogenesis InhibitorsReview ArticleBiologyBioinformaticsGeneral Biochemistry Genetics and Molecular BiologyNUCLEAR EXPORTTUMOR ANGIOGENESISNeovascularizationMicroprocessor complexSMALL RNASDownregulation and upregulationNeoplasmsmicroRNAGene expressionmedicineAnimalsHumansMolecular Targeted TherapyPrecision MedicineIN-VIVOGENE-EXPRESSIONGeneral Immunology and MicrobiologyNeovascularization PathologicCell growthlcsh:RMICROBIOLOGIAGeneral MedicineMICROPROCESSOR COMPLEXMicroRNAsENDOTHELIAL GROWTH-FACTORCancer researchmedicine.symptom
researchProduct

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer

2012

Recent work identified L-asparaginase (L-ASP) as a putative therapeutic target for ovarian cancer. We suggest that L-ASP, a dysregulator of glycosylation, would interrupt the local microenvironment, affecting the ovarian cancer cell-endothelial cell interaction and thus angiogenesis without cytotoxic effects. Ovarian cancer cell lines and human microvascular endothelial cells (HMVEC) were exposed to L-ASP at physiologically attainable concentrations and subjected to analyses of endothelial tube formation, invasion, adhesion and the assessment of sialylated proteins involved in matrix-associated and heterotypic cell adhesion. Marked reduction in HMVEC tube formation in vitro, HMVEC and ovari…

Cell typeautophagyGlycosylationAngiogenesisCellOligosaccharidesAngiogenesis InhibitorsBiologyL-asparaginase; ovarian cancer; angiogenesisCell-Matrix JunctionsangiogenesisSettore BIO/13 - Biologia ApplicataCell Line TumorE-selectinmedicineCell AdhesionHumansCell adhesionSialyl Lewis X AntigenTube formationOvarian NeoplasmsNeovascularization PathologicIntegrin beta1AutophagyEndothelial CellsCell BiologyOriginal Articlesmedicine.diseaseasparaginaseL-asparaginaseCell biologymedicine.anatomical_structureovarian cancersialyl Lewis Xbiology.proteinMolecular MedicineFemaleOvarian cancerE-Selectin
researchProduct